



**Editor-in-Chief**

**Joseph Miano**

Augusta University, United States of America

**Senior Associate Editor**

**Rosalinda Madonna**

University of Pisa, Italy

**Associate Editors**

**Andrew Baker**

The University of Edinburgh, United Kingdom

**Kathleen Martin**

Yale School of Medicine,

United States of America

**Gerard Pasterkamp**

Utrecht University, Netherlands

**Carmine Dario Vizza**

University of Rome La Sapienza, Italy

**Cang Bao Xu**

Xi'an Medical University, China

# Vascular Pharmacology

## A Journal of Vascular Biology and Medicine

*Vascular Pharmacology* publishes original papers on all aspects of the biology, pathology, and pharmacology of the vascular system.

Papers are encouraged in basic, translational, and clinical aspects of Vascular Biology and Medicine, utilizing state-of-the-art approaches in animal modeling, gene/genome editing, genomics and next generation sequencing, human genetics, integrative physiology, and molecular biology. All papers are in English.

The Journal is particularly interested in scholarly review articles on emerging concepts and paradigm shifts in the vascular system related to atherosclerosis, cell signaling, disease modeling, genetics and genomics, inflammation, lipid metabolism, pharmacology, and thrombosis.


## Open access options

*Vascular Pharmacology* offers authors two choices to publish their research:

1. Gold open access: Articles are freely available to both subscribers and the wider public with permitted reuse. An **open access publication fee** is payable by authors or their research funder.
2. Articles are made available to subscribers as well as developing countries and patient groups through our access programs. **No open access publication fee.**



Visit the journal homepage:  
<https://www.journals.elsevier.com/vascular-pharmacology>



#### Consulting Editors

**David Fulton**

Augusta University, United States of America

**Peter Libby**

Harvard Medical School, United States of America

**Dianna Milewicz**

The University of Texas System,  
United States of America

**Ryozo Nagai**

The University of Tokyo, Japan

**Eric Olson**

The University of Texas Southwestern Medical  
Center, United States of America

2021 Impact Factor\*

**5.738**

\*Journal Citation Reports®  
(Clarivate Analytics, 2022)



ELSEVIER

# Vascular Pharmacology

## MOST CITED ARTICLES

**Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease**

Volume 112, January 2019, Pages 54-71

Eithne M. Maguire, Stuart W.A. Pearce, Qingzhong Xiao

**Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis**

Volume 113, February 2019, Pages 86-91

Amr Shaaban Hanafy, Sherief Abd-Elsalam, Mohammed M. Dawoud

**lncRNAs in vascular biology and disease**

Volume 114, March 2019, Pages 145-156

Viorel Simion, Stefan Haemmig, Mark W. Feinberg

## MOST DOWNLOADED ARTICLES

**Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study**

Volume 144, June 2022, 106975

Evangelos Oikonomou, Nektarios Souvaliotis, Stamatios Lampsas et al.

**Decreased NO production in endothelial cells exposed to plasma from ME/CFS patients**

Volume 143, April 2022, 106953

Romina Bertinat, Roberto Villalobos-Labra, Lidija Hofmann et al.

**SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells**

Volume 137, April 2021, 106823

Yuichiro J. Suzuki, Sofia I. Nikolaienko, Vyacheslav A. Dibrova et al.

## SUPPORTS OPEN ACCESS

Journal offers authors the option to publish papers open access. See the journal homepage for details: <https://www.journals.elsevier.com/vascular-pharmacology>

Visit the journal homepage:

<https://www.journals.elsevier.com/vascular-pharmacology>